Debate about the optimal management of actinic keratoses shows no signs of abating. On 21 March 2013, a group of leading dermatologists met to discuss issues affecting clinical practice. This meeting report reflects their views and is accompanied by five short videos.

Ergebnisse des Onkoderm-Workshops „Praxisorientierte aktinische Keratose-Behandlung in der Fläche“ im Dezember 2012 in Bonn. Onkoderm-Teilnehmer: Prof. Dr. med. Uwe Reinhold, Dr. med. Ralph von Kiedrowski, Dr. med. Hanspeter Prieur, Dr. med. Peter Radny, Dr. med. Lutz Schmitz (in Vertretung von Prof. Dr. med. Thomas

Dirschka)

This KOM focuses on the role of imiquimod 3.75% cream, a new field-directed treatment, in the management of actinic keratosis.

Vorbericht der DDG-Tagung in Dresden im April 2013.

Preview of the German Society for Dermatology (DDG) meeting in Dresden in April 2013.

Addressing the current challenges involved in the treatment of acute and life-threatening bleeding is key for improving patient outcomes. The timing and nature of the haemostatic interventions are currently in focus. Recent military experience has brought massive transfusion protocols into the civilian setting, while improved point-of-care technologies and the wide availability of purified clotting factor concentrates now allow for the implementation of early, targeted, goal-directed therapy. The evidence supporting the use of these approaches was critically appraised by four leading experts at a CSL Behring-sponsored satellite symposium entitled: ‘The challenge of rapid and targeted treatment of acute bleeding’ at the European Society of Anaesthesiology Congress (Euroanaesthesia 2012), and the benefits of a multidisciplinary approach to coagulation management were highlighted.